Ondřej Lebeda, Kateřina Ondrák Fialová, Lukáš Ondrák, Jaroslav Červenák, Jan Ráliš, Jan Štursa
{"title":"Cross sections of the <sup>226</sup>Ra(p,xn) reactions relevant for <sup>225</sup>Ac production.","authors":"Ondřej Lebeda, Kateřina Ondrák Fialová, Lukáš Ondrák, Jaroslav Červenák, Jan Ráliš, Jan Štursa","doi":"10.1016/j.nucmedbio.2025.108995","DOIUrl":null,"url":null,"abstract":"<p><p>Limited availability constrains the implementation of <sup>225</sup>Ac, the most promising α emitter for targeted therapy, in clinical practice. Proton activation of <sup>226</sup>Ra is one of few realistic solutions to this problem. We have therefore measured cross sections of relevant <sup>226</sup>Ra(p,xn) nuclear reactions in the energy range of 12.0 to 17.2 MeV. The obtained results allowed us to deduce the yield of <sup>224</sup>Ac, <sup>225</sup>Ac, and <sup>226</sup>Ac. The consequences of our data to predictions of production capacity and radionuclidic purity of <sup>225</sup>Ac are thoroughly discussed, and their comparison with previous measurements and with the prediction of the TALYS 1.96 nuclear reaction model code run with default parameters are provided.</p>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"142-143 ","pages":"108995"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.nucmedbio.2025.108995","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Limited availability constrains the implementation of 225Ac, the most promising α emitter for targeted therapy, in clinical practice. Proton activation of 226Ra is one of few realistic solutions to this problem. We have therefore measured cross sections of relevant 226Ra(p,xn) nuclear reactions in the energy range of 12.0 to 17.2 MeV. The obtained results allowed us to deduce the yield of 224Ac, 225Ac, and 226Ac. The consequences of our data to predictions of production capacity and radionuclidic purity of 225Ac are thoroughly discussed, and their comparison with previous measurements and with the prediction of the TALYS 1.96 nuclear reaction model code run with default parameters are provided.
期刊介绍：
Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
